Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

NCT02186821 ·Status: TERMINATED ·Phase: PHASE2

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NCT04318938 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874 ·Status: NO_LONGER_AVAILABLE

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NCT06552234 ·Status: RECRUITING ·Phase: PHASE2

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

NCT05770544 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02064491 ·Status: COMPLETED ·Phase: PHASE2

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

NCT01472003 ·Status: COMPLETED ·Phase: PHASE1

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

NCT02040064 ·Status: COMPLETED ·Phase: PHASE1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

NCT07085091 ·Status: RECRUITING ·Phase: PHASE1

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

NCT03178071 ·Status: NO_LONGER_AVAILABLE

A Study of ABT-806 in Subjects With Advanced Solid Tumor Types

NCT01255657 ·Status: COMPLETED ·Phase: PHASE1

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

NCT02616211 ·Status: COMPLETED

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

NCT02927340 ·Status: UNKNOWN ·Phase: PHASE2

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00101920 ·Status: COMPLETED ·Phase: PHASE2

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

NCT06713798 ·Status: WITHDRAWN ·Phase: PHASE2

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

NCT04036682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

NCT04146571 ·Status: AVAILABLE

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

NCT01449461 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

NCT02047903 ·Status: COMPLETED

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02289833 ·Status: COMPLETED ·Phase: PHASE2

RT Plus EGFR-TKI for Wild-type NSCLC

NCT02738983 ·Status: UNKNOWN ·Phase: PHASE2

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

NCT01147211 ·Status: UNKNOWN ·Phase: PHASE1